{
    "nctId": "NCT00749437",
    "briefTitle": "Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer",
    "officialTitle": "Feasibility of 3-D Conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage, Node Negative Breast Cancer Patients Using Acculoc Fiducial Markers: A Phase I Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Amount of the shifts of the radiation fields based on bony anatomy as compared to that of gold fiducial markers",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nInclusion criteria:\n\n* Histologically confirmed ductal carcinoma in situ or invasive carcinoma of the breast (including ductal, medullary, papillary, colloid \\[mucinous\\], or tubular histologies) meeting all of the following criteria:\n\n  * AJCC stage 0, I, or II (Tis, T1N0, or T2N0) disease with a lesion \u2264 3 cm treated with lumpectomy and either sentinel node biopsy or axillary dissection (if invasive carcinoma is present)\n  * Unifocal breast cancer (i.e., single focus that can be encompassed by one lumpectomy)\n* Underwent or plan to undergo lumpectomy with placement of gold fiducial markers (markers placed concurrently with the surgery or on a later date)\n\n  * Patients who has underwent lumpectomy must meet all of the following criteria:\n\n    * Must be enrolled between 14-60 days from date of last surgery, and radiation must start within 15-80 days of date of last surgery\n    * Four to six gold fiducial markers placed in the tumor bed, delineating the margins of the lumpectomy cavity\n    * Negative, inked histologic margins of lumpectomy (\\> 1 mm) or re-excision specimen to be confirmed prior to radiation\n\n      * Margins are unacceptable if there is invasive or non-invasive tumor within 1 mm of the inked margin\n* Negative post-excision mammography if malignancy-associated microcalcifications were initially present\n* Hormone receptor status not specified\n\nExclusion criteria:\n\n* Evidence of suspicious microcalcifications in the breast prior to the start of radiation\n* One or more positive axillary nodes or positive sentinel biopsy\n* Distant metastases\n* Invasive or extensive in-situ lobular carcinoma or non-epithelial breast malignancies such as sarcoma or lymphoma\n* Proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy\n* Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor\n* Paget's disease of the nipple\n* Skin involvement, regardless of tumor size\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* ECOG performance status 0-1\n* Life expectancy \u2265 2 years\n* Not pregnant or nursing\n* No prior treated breast carcinoma within the past 5 years\n* No collagen vascular diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis\n* No co-existing medical conditions\n* No patients with medical conditions that would preclude compliance with the trial, as determined by the investigator\n* No other malignancy, except non-melanomatous skin cancer, within the past 5 years\n\n  * Disease-free interval from any prior carcinoma must be continuous\n* No breast technically unsuitable for radiotherapy\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Concurrent tamoxifen citrate, anastrozole, or other hormonal therapy allowed\n* Future chemotherapy allowed provided it is administered after the APBI and begins no earlier than 2 weeks after completion of radiotherapy\n* No tylectomies so extensive that the cosmetic result is low or poor prior to radiation\n* No prior radiation to the ipsilateral breast\n* No prior non-hormonal therapy or radiotherapy for this disease\n* No chemotherapy in the past 2 weeks\n* No concurrent chemotherapy, immunotherapy, or experimental medications",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}